On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.
IBD's proprietary RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves. See if Bristol Myers Squibb stock can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Is Bristol Myers Squibb Stock A Buy?
Bristol Myers Squibb stock is not currently near a potential buying area. See if the drug stock goes on to form a sound pattern that could launch a new move.
The drug maker company showed -10% EPS growth last quarter. Sales gains came in at 8%.
Bristol Myers Squibb stock holds the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health and AbbVie are also among the group's highest-rated stocks.
